THIRD WORLD NETWORK BIOSAFETY INFORMATION SERVICE
The African Centre for Biodiversity
PO Box 29170, Melville 2109 South Africa
Tel: +27 (0)11 486 1156
Dear Friends and colleagues,
Press Release from the African Centre for Biodiversity
AU’s premature and misguided endorsement of controversial, unproven gene drive mosquitos for malaria ‘eradication’ in Africa
Johannesburg, Monday, 5 November 2018
The African Union (AU) is paving the way for the entry of the latest and most controversial form of genetic engineering, gene drive technologies. In July 2018 the AU released a report endorsing the development of the technology as well as ‘enabling legislation’ for their deployment across its member states. The African Centre for Biodiversity (ACB), has today released its critique of the AU report, which the ACB says is hopelessly premature and merely repeats unsubstantiated claims made by gene drive developers.
Gene drives are an extreme form of genetic modification (GM), designed to alter the genetics of an entire population, with the potential to eradicate entire mosquito populations. Such a technology has stirred intense public, policy, legal and ethical debates about the potential impacts on the environment and health.
Executive Director of the ACB, Mariam Mayet, warns that, “this technology is in its infancy; the long term impacts on the mosquito populations (the disease vectors) and human health, as well as their potential ecological impacts are completely unknown. It is also clear that once released, the technology cannot be recalled due to its aggressive nature, which overrides natural inheritance patterns. Of course mosquitos will also not respect borders”.
Gene drives – a technology in its infancy
Their potential for eradicating malaria, a serious health challenge in Africa, remains highly speculative. Current evidence demonstrating their potential as a sound tool for malaria eradication is yet to be demonstrated, with some developers admitting that they are likely to face technical problems that may well hinder their effectivity.
Despite the lack of underlying data demonstrating their potential efficacy, grand claims of gene drives being a ‘game-changer’ are nevertheless being made by developers, and supported by AU statements that they present ‘realistic options for effective disease control’ and that ‘potential benefits for African countries will almost certainly be extensive’.
GM mosquitos to be released in Burkina Faso
Such claims have already opened the door for gene drive research groups such as the Target Malaria project, funded by the Gates Foundation and the Open Philanthropy project, to release other forms of genetically modified mosquitos in Burkina Faso, due to be trialled in the very near future - the first ever GM animal on the continent - showing callous disregard for its people, the environment or the concerns of many scientists about potentially harmful impacts. The GM mosquitoes have no public health benefit and are meant to ‘test’ biosafety systems and prepare the way for the future release of gene drive mosquitoes. In the meanwhile, research is already taking place that pays volunteers to expose themselves to wild-type mosquitos for paltry sums (around $4.20 per night for six hours) increasing risk of malaria exposure to themselves and others.
Colonial medicine and corporate profits
The hype and media pressure surrounding gene drives as the latest techno-fix fails to take into account lessons from history. As witnessed with previous malaria eradication programs, while sometimes effective in significantly reducing mosquito populations, they did not always translate to reduced disease burden. Further, numerous African successes in malaria reductions were largely ephemeral, in some cases even resulting in surges of cases amongst vulnerable populations that had lost acquired immunity to the disease.
According to Mayet, “the Target Malaria project represents the latest version of a top-down approach rooted in a bygone era of colonial medicine that laid the foundations for global health policies. It yet again focuses narrowly on technologies, while strategies that focus on wider determinants of health such as investments in national health services are being neglected, despite their critical influence in past global successes.”
It also appears that a public health application is being specifically chosen as the first potential deployment of gene drives despite wider corporate interest in the technology, in attempts to gain public and government support. Sabrina Masinjila, researcher and advocacy officer with the ACB based in Dar es Salaam points out that “gene drives are being targeted for Africa before anywhere else in the world. Despite this being on the face of it, a ‘philanthropic’ venture to combat a serious public health issue, profits from future gene drive applications especially in agriculture, may well come off the backs of human experiments that first risked the health of the people of Burkina Faso”.
No public debate on irreversible technology
The AU report endorsing gene drive applied research and potential deployment for malaria eradication has emerged in the absence of any agreed international governance standards for the release of the mosquitoes into the environment. The AU has also been deaf to any form of civil society concerns or debate, despite the fact that this technology cannot be recalled once it is deployed.
In 2016 over 170 international civil society organisations called for a moratorium on gene drive releases, including applied research such as open field trial releases, until there is further understanding of the potential risks and technical issues. Concerns remain regarding the inability to regulate transboundary movement; the inability to contain gene drive organisms following both field trial and commercial releases; issues surrounding monitoring, assessment and liability; and the need for free, prior and informed consent, particularly with regards to lands and territories of indigenous and local communities as enshrined in the UN Declaration on the Rights of Indigenous Peoples.
The ACB supports this call for a moratorium and strongly urges African governments to do the same at the upcoming 14th meeting of the Conference of the Parties to the Convention on Biological Diversity due to take place in Sharm El -Sheikh, Egypt 17-29 November 2018.
Contact: Fatima Gabru, media and communications officer at the ACB: Email firstname.lastname@example.org
The press release and critique are available in French as well
The ACB Team